Success Story: NAILG Supports Biotechnology Researcher Through RFE to EB-1A Approval
Client’s Testimonial:
"This is wonderful news! All of the efforts and hard work have truly paid off. I would like to sincerely thank the entire team for their support, dedication, and outstanding work throughout this process."
On July 16th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an Associate Specialist in the Field of Biotechnology (Approval Notice).
General Field: Biotechnology
Position at the Time of Case Filing: Associate Specialist
Country of Origin: India
Country of Residence at the Time of Filing: California
Approval Notice Date: July 16th, 2026
Processing Time: 3 months, 20 days (Premium Processing Requested)
Case Summary:
The client filed an EB-1A petition on March 26th, 2026, seeking classification as an individual of extraordinary ability in biotechnology. Only eight days later, on April 3rd, USCIS issued a Request for Evidence (RFE), placing the petition under additional scrutiny. The case ultimately received approval on July 16th, 2026, after North America Immigration Law Group (Chen Immigration Law Associates) addressed the RFE and presented the client's record within the EB-1A framework.
At the time of filing, the client was employed as an associate specialist conducting biotechnology research focused on molecular and cellular processes vital to human health. Her past work encompassed the study of complex cellular signaling and molecular interactions, alongside foundational research into biological systems with broader environmental and energy applications. Her current research investigates fundamental molecular mechanisms, offering significant potential to advance treatments in chronic disease management, oncology, and regenerative medicine.
The RFE made it especially important to demonstrate the client's standing through more than the existence of publications or citations alone. Her record included 16 peer-reviewed journal articles and 1 first-authored preprint. Her research had accumulated 593 citations, and the submitted evidence indicated that researchers in at least 53 countries had cited her publications. Two of her papers also showed particularly strong citation performance relative to other publications from their respective years, including one identified among the top 1% of cited papers in their subject category. Her judging activity provided another dimension of professional recognition. The client had completed at least 31 peer reviews for scholarly journals and served on the editorial board of a scientific journal. North America Immigration Law Group incorporated this evidence into the broader record to demonstrate that her expertise had been repeatedly called upon in evaluating the work of other researchers.
The record also showed that portions of her research had received support from major governmental research organizations in the United States and abroad. Four expert letters supplemented this objective evidence, three of which were independent advisory opinions from researchers who knew the client's work through the scientific literature rather than through direct collaboration.
Responding to the RFE therefore required the evidence to be considered as an interconnected record. The client's authorship, citation impact, peer-review service, editorial responsibilities, independent use of her discoveries, research support, and expert testimony collectively documented recognition extending beyond her immediate professional environment. This evidence also supported the final merits analysis concerning sustained national or international acclaim and her standing within biotechnology.
The outcome demonstrates how an RFE can require a petitioner's existing accomplishments to be contextualized more precisely under the demanding EB-1A standard, particularly by showing not merely what the researcher has accomplished, but how those accomplishments have been recognized and relied upon throughout the field.